HIGHLIGHTS
- who: Mojtaba Porbahaie and collaborators from the Cell Biology and Immunology Group, Wageningen University and Research, Wageningen, The Netherlands have published the research work: Low doses of diarrhoeagenic E. coli induce enhanced monocyte and mDC responses and prevent development of symptoms after homologous rechallenge, in the Journal: PLOS ONE
- what: The authors aimed to identify the lowest dose capable of conferring protection against the second challenge. The study was approved by the Medical Ethics Committee (METC) of Brabant (Tilburg, the Netherlands) and was conducted according to the Declaration of Helsinki and was registered at www . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.